Dan Leonard
Stock Analyst at UBS
(4.09)
# 523
Out of 5,090 analysts
308
Total ratings
57.47%
Success rate
10.05%
Average return
Main Sectors:
Stocks Rated by Dan Leonard
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| A Agilent Technologies | Maintains: Buy | $170 → $180 | $148.32 | +21.36% | 23 | Nov 25, 2025 | |
| TXG 10x Genomics | Maintains: Neutral | $13 → $14 | $18.11 | -22.69% | 7 | Nov 7, 2025 | |
| TECH Bio-Techne | Maintains: Buy | $65 → $70 | $63.37 | +10.46% | 12 | Nov 6, 2025 | |
| BRKR Bruker | Maintains: Neutral | $40 → $43 | $48.22 | -10.83% | 12 | Nov 4, 2025 | |
| GH Guardant Health | Maintains: Buy | $80 → $110 | $108.75 | +1.15% | 11 | Oct 30, 2025 | |
| IQV IQVIA Holdings | Maintains: Buy | $225 → $250 | $224.92 | +11.15% | 17 | Oct 29, 2025 | |
| TMO Thermo Fisher Scientific | Maintains: Neutral | $500 → $590 | $575.24 | +2.57% | 18 | Oct 23, 2025 | |
| EXAS Exact Sciences | Maintains: Neutral | $61 → $53 | $101.15 | -47.60% | 10 | Aug 7, 2025 | |
| CERT Certara | Maintains: Buy | $18 → $15 | $9.57 | +56.82% | 10 | Aug 7, 2025 | |
| MEDP Medpace Holdings | Downgrades: Sell | $300 → $305 | $541.06 | -43.63% | 2 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $225 | $227.13 | -0.94% | 18 | Jul 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $1,530 → $1,350 | $1,422.81 | -5.12% | 9 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $355 → $310 | $320.06 | -3.14% | 20 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $355 → $310 | $319.10 | -2.85% | 20 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $145 → $115 | $102.55 | +12.14% | 2 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $122 → $99 | $91.96 | +7.66% | 1 | Apr 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $29 → $25 | $11.15 | +124.22% | 7 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $250 → $185 | $184.04 | +0.52% | 6 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $7 → $9 | $9.80 | -8.16% | 2 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $35 | $28.29 | +23.72% | 4 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $225 → $200 | $127.80 | +56.49% | 16 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $11 | $3.73 | +194.91% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $70 | $242.83 | -71.17% | 7 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $7 | $17.31 | -59.56% | 2 | Feb 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $345 | $396.37 | -12.96% | 12 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $260 | $185.45 | +40.20% | 5 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $160 → $145 | $184.18 | -21.27% | 10 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $95 → $90 | $74.86 | +20.23% | 12 | Feb 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $62 → $64 | $47.08 | +35.20% | 3 | Dec 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $330 → $340 | $261.48 | +30.03% | 11 | Dec 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $24 | $22.92 | +4.71% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $45 → $35 | $7.31 | +379.12% | 12 | Aug 14, 2019 |
Agilent Technologies
Nov 25, 2025
Maintains: Buy
Price Target: $170 → $180
Current: $148.32
Upside: +21.36%
10x Genomics
Nov 7, 2025
Maintains: Neutral
Price Target: $13 → $14
Current: $18.11
Upside: -22.69%
Bio-Techne
Nov 6, 2025
Maintains: Buy
Price Target: $65 → $70
Current: $63.37
Upside: +10.46%
Bruker
Nov 4, 2025
Maintains: Neutral
Price Target: $40 → $43
Current: $48.22
Upside: -10.83%
Guardant Health
Oct 30, 2025
Maintains: Buy
Price Target: $80 → $110
Current: $108.75
Upside: +1.15%
IQVIA Holdings
Oct 29, 2025
Maintains: Buy
Price Target: $225 → $250
Current: $224.92
Upside: +11.15%
Thermo Fisher Scientific
Oct 23, 2025
Maintains: Neutral
Price Target: $500 → $590
Current: $575.24
Upside: +2.57%
Exact Sciences
Aug 7, 2025
Maintains: Neutral
Price Target: $61 → $53
Current: $101.15
Upside: -47.60%
Certara
Aug 7, 2025
Maintains: Buy
Price Target: $18 → $15
Current: $9.57
Upside: +56.82%
Medpace Holdings
Jul 29, 2025
Downgrades: Sell
Price Target: $300 → $305
Current: $541.06
Upside: -43.63%
Jul 23, 2025
Maintains: Buy
Price Target: $240 → $225
Current: $227.13
Upside: -0.94%
May 20, 2025
Upgrades: Buy
Price Target: $1,530 → $1,350
Current: $1,422.81
Upside: -5.12%
May 2, 2025
Maintains: Buy
Price Target: $355 → $310
Current: $320.06
Upside: -3.14%
May 2, 2025
Maintains: Buy
Price Target: $355 → $310
Current: $319.10
Upside: -2.85%
May 1, 2025
Upgrades: Buy
Price Target: $145 → $115
Current: $102.55
Upside: +12.14%
Apr 7, 2025
Maintains: Overweight
Price Target: $122 → $99
Current: $91.96
Upside: +7.66%
Jan 17, 2025
Downgrades: Neutral
Price Target: $29 → $25
Current: $11.15
Upside: +124.22%
Jan 17, 2025
Downgrades: Neutral
Price Target: $250 → $185
Current: $184.04
Upside: +0.52%
Oct 18, 2024
Maintains: Neutral
Price Target: $7 → $9
Current: $9.80
Upside: -8.16%
Dec 7, 2023
Initiates: Neutral
Price Target: $35
Current: $28.29
Upside: +23.72%
Aug 10, 2023
Maintains: Neutral
Price Target: $225 → $200
Current: $127.80
Upside: +56.49%
Aug 8, 2023
Maintains: Neutral
Price Target: $14 → $11
Current: $3.73
Upside: +194.91%
Aug 4, 2023
Reiterates: Outperform
Price Target: $70
Current: $242.83
Upside: -71.17%
Feb 15, 2023
Reiterates: Underperform
Price Target: $7
Current: $17.31
Upside: -59.56%
Aug 25, 2022
Initiates: Neutral
Price Target: $345
Current: $396.37
Upside: -12.96%
Aug 25, 2022
Initiates: Neutral
Price Target: $260
Current: $185.45
Upside: +40.20%
Feb 4, 2022
Maintains: Equal-Weight
Price Target: $160 → $145
Current: $184.18
Upside: -21.27%
Feb 3, 2022
Maintains: Overweight
Price Target: $95 → $90
Current: $74.86
Upside: +20.23%
Dec 14, 2021
Maintains: Equal-Weight
Price Target: $62 → $64
Current: $47.08
Upside: +35.20%
Dec 14, 2021
Maintains: Overweight
Price Target: $330 → $340
Current: $261.48
Upside: +30.03%
Aug 10, 2021
Initiates: Overweight
Price Target: $24
Current: $22.92
Upside: +4.71%
Aug 14, 2019
Maintains: Hold
Price Target: $45 → $35
Current: $7.31
Upside: +379.12%